Trial
NCT02124902
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
National Institutes of Health (NIH); National Cancer Institute (NCI); Breast Cancer Research Foundation; NeoImmuneTech
Condition
Triple Negative Breast Neoplasms
Intervention
Docetaxel
Why stopped
Insufficient funding/staff
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-07